Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults

…, G Deschênes, Y Lebranchu, J Zuber… - Clinical Journal of the …, 2013 - journals.lww.com
Results Onset of aHUS occurred as frequently during adulthood (58.4%) as during childhood
(41.6%). The percentages of patients who developed the disease were 23%, 40%, 70%, …

[HTML][HTML] Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies

…, S Ngo, MA Dragon-Durey, MA Macher, J Zuber… - Kidney international, 2012 - Elsevier
Dense deposit disease and glomerulonephritis with isolated C3 deposits are glomerulopathies
characterized by deposits of C3 within or along the glomerular basement membrane. …

Haemolytic uraemic syndrome

F Fakhouri, J Zuber, V Frémeaux-Bacchi, C Loirat - The Lancet, 2017 - thelancet.com
Haemolytic uraemic syndrome is a form of thrombotic microangiopathy affecting predominantly
the kidney and characterised by a triad of thrombocytopenia, mechanical haemolytic …

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

J Zuber, F Fakhouri, LT Roumenina, C Loirat… - Nature Reviews …, 2012 - nature.com
In the past decade, a large body of evidence has accumulated in support of the critical role
of dysregulation of the alternative complement pathway in atypical haemolytic uraemic …

[HTML][HTML] Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation

J Zuber, M Le Quintrec, S Krid, C Bertoye… - American Journal of …, 2012 - Elsevier
Eculizumab (anti-C5) has been sporadically reported as an efficient therapy for atypical
hemolytic uremic syndrome (aHUS). However, the lack of series precludes any firm conclusion …

New insights into postrenal transplant hemolytic uremic syndrome

J Zuber, M Le Quintrec, R Sberro-Soussan… - Nature Reviews …, 2011 - nature.com
After renal transplantation, hemolytic uremic syndrome (HUS) may occur either as a recurrent
or de novo form. Over the past decade, much effort has been devoted to elucidating the …

Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients

…, T Kawai, W Wong, S Yang, J Zuber… - Science translational …, 2015 - science.org
T cell responses to allogeneic major histocompatibility complex antigens present a formidable
barrier to organ transplantation, necessitating long-term immunosuppression to minimize …

Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept

…, D Anglicheau, J Izopet, C Couat, J Zuber… - …, 2021 - journals.lww.com
Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 In... : Transplantation Poor
Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in …

[HTML][HTML] Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept

…, L Bererhi, F Lanternier, C Legendre, J Zuber… - American Journal of …, 2021 - Elsevier
Poor responses to mRNA COVID-19 vaccine have been reported after 2 vaccine injections
in kidney transplant recipients (KTRs) treated with belatacept. We analyzed the humoral …

Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study

A Loupy, C Suberbielle-Boissel, J Zuber… - …, 2010 - journals.lww.com
Background. This study assesses the immunologic, functional, and histologic course of kidney
recipients with preformed donor-specific alloantibodies (DSA) receiving deceased donor …